Urine TITIN N-fragment as a novel biomarker for critical illness myopathy: a pilot study

Table 1 Basic characteristics and results for each patient

No.	Age	Sex	Diagnosis	SOFA	APACHEII	Hospital stay	ICU stay	Days on MV until day 10	Total steroids dose until day 10	RRT	Muscle relaxant use	Outcome	BI at day 28	CK (U/L)†	Cre (mg/dL)†	N-titin/Cre (pmol/mgCre/dL)*	FMM change (%)
1	86	F	Bacrerial pneumonia	6	15	20	9	5	PSL 150 mg	–	–	Alive	0	42.3	0.82	42.93	− 28.65
2	48	M	Interstitial pneumonia	6	9	91	15	10	PSL 360 mg mPSL 4000 mg	–	–	Alive	10	206.4	0.65	42.33	− 19.03
3	86	F	Congestive heart failure	7	20	11	5	2	PSL 180 mg	–	–	Alive	80	72.1	0.82	21.62	− 14.28
4	60	M	Malignant lymphoma	8	11	33	14	9	PSL 160 mg HYD 1200 mg	–	–	Alive	65	31.7	0.57	29.69	− 20.96

SOFA Sequential Organ Failure Assessment, APACHE II Acute Physiological and Chronic Health Evaluation II, MV mechanical ventilation, RRT renal replacement therapy, BI Barthel Index, CK creatine kinase, N-titin urine titin N-fragment, Cre serum creatinine, FMM femoral muscle mass, PSL prednisolone, mPSL methyl predonisolone, HYD hydrocortisone
*is for N-titin/Cre(pmol/mgCre/dL); ^†is for CK and Cre

ISSN: 1364-8535